Research and Markets: Commercial Insight: Parkinson's Disease - Japan and Europe to Drive Total Market Growth

* Reuters is not responsible for the content in this press release.

Wed Oct 28, 2009 10:00pm EDT

DUBLIN--(Business Wire)--
Research and Markets
(http://www.researchandmarkets.com/research/7f327f/commercial_insight) has
announced the addition of the "Commercial Insight: Parkinson's Disease - Japan
and Europe to Drive Total Market Growth" report to their offering. 

The Parkinson's disease market is approaching maturity, with the threat of
generic incursion evident in each drug class. Although growth will be stifled by
generic launches, relatively successful lifecycle management strategies and new
product launches see the Parkinson's disease market grow at a compound annual
growth rate (CAGR) of 2.6% over the next 10 years (20082018). 

Scope:

* In-depth analysis of the current and future Parkinson's disease market across
the US, Japan, France, Germany, Italy, Spain and the UK. 
* Parkinson's disease-specific sales forecasts for brands and generics from 2008
to 2018. 
* Assessment of the leading Parkinson's disease brands and drug classes to
identify key success factors within this market. 
* Evaluation of the strategies of leading players in the Parkinson's disease
market.

Highlights of this title:

* Stalevo's clear convenience and compliance benefit will see the combination
therapy emerge as the market leading brand between 2011 and 2013. 
* Although Boehringer Ingelheim is relatively late to the market with a
once-daily reformulation, Mirapex/Sifrol's (pramipexole) dominant share of some
geographic markets will facilitate a successful launch in 2010. 
* Over the 10-year forecast period the US market will lose significance for
Parkinson's disease market players as demographic changes and a less competitive
commercial environment will see the European and Japanese markets emerge as key
generators of growth.

Key reasons to purchase this title:

* Quantify the performance of each of the marketed Parkinson's disease drugs in
the seven major markets over the period 2008 to 2018. 
* Assess the changing key opportunities and threats affecting current market
players and prospective new entrants. 
* Identify the leading brands in this market over the next 10 years and
understand the key factors driving their success.

Key Topics Covered:

Chapter 1 Executive Summary 

Chapter 2 Market Definition 

Chapter 3 Market Overview 

Chapter 4 Brand Dynamics 

Chapter 5 Key Developers 

Chapter 6 Case Studies 

For more information visit
http://www.researchandmarkets.com/research/7f327f/commercial_insight

Source: Datamonitor

Research and Markets
Laura Wood, Senior Manager,
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716 

Copyright Business Wire 2009

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.